Aflibercept may be a better option in BRVO

W. Lloyd Clark, MD, reported new clinical data at Retina Subspecialty Day that showed more patients with macular edema following branch retinal vein occlusion (BRVO) gained vision following intravitreal aflibercept treatment compared with laser.

Phase 3 VIBRANT study results showed that 53 percent of patients who received 2 mg of aflibercept every four weeks gained at least 15 letters in vision from baseline at week 24, compared to 27 percent of patients who received laser (p < 0.001).  Additionally, aflibercept-treated patients achieved a 17.0 letter mean improvement over baseline in best corrected visual acuity compared to a 6.9 letter mean improvement in patients who received laser (p < 0.0001).